Literature DB >> 29867221

Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer.

Jenny Karlsson1, Anders Valind1, Linda Holmquist Mengelbier1, Sofia Bredin1, Louise Cornmark1, Caroline Jansson1, Amina Wali1, Johan Staaf2, Björn Viklund3, Ingrid Øra4, Anna Börjesson5, Torbjörn Backman5, Noémie Braekeveldt6, Bengt Sandstedt7, Niklas Pal7, Anders Isaksson3, Barbara Gürtl Lackner8, Tord Jonson1, Daniel Bexell6,8, David Gisselsson9,10,11.   

Abstract

A major challenge to personalized oncology is that driver mutations vary among cancer cells inhabiting the same tumor. Whether this reflects principally disparate patterns of Darwinian evolution in different tumor regions has remained unexplored1-5. We mapped the prevalence of genetically distinct clones over 250 regions in 54 childhood cancers. This showed that primary tumors can simultaneously follow up to four evolutionary trajectories over different anatomic areas. The most common pattern consists of subclones with very few mutations confined to a single tumor region. The second most common is a stable coexistence, over vast areas, of clones characterized by changes in chromosome numbers. This is contrasted by a third, less frequent, pattern where a clone with driver mutations or structural chromosome rearrangements emerges through a clonal sweep to dominate an anatomical region. The fourth and rarest pattern is the local emergence of a myriad of clones with TP53 inactivation. Death from disease was limited to tumors exhibiting the two last, most dynamic patterns.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29867221     DOI: 10.1038/s41588-018-0131-y

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  22 in total

Review 1.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

Authors:  E Alejandro Sweet-Cordero; Jaclyn A Biegel
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

Review 2.  Computational Approaches for the Investigation of Intra-tumor Heterogeneity and Clonal Evolution from Bulk Sequencing Data in Precision Oncology Applications.

Authors:  Alessandro Laganà
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 4.  Sensitivity and specificity of information criteria.

Authors:  John J Dziak; Donna L Coffman; Stephanie T Lanza; Runze Li; Lars S Jermiin
Journal:  Brief Bioinform       Date:  2020-03-23       Impact factor: 11.622

Review 5.  Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies.

Authors:  Kristina Ihrmark Lundberg; Diana Treis; John Inge Johnsen
Journal:  Curr Oncol Rep       Date:  2022-04-01       Impact factor: 5.945

6.  Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.

Authors:  Sofie Mohlin; Karin Hansson; Katarzyna Radke; Sonia Martinez; Carmen Blanco-Apiricio; Cristian Garcia-Ruiz; Charlotte Welinder; Javanshir Esfandyari; Michael O'Neill; Joaquin Pastor; Kristoffer von Stedingk; Daniel Bexell
Journal:  EMBO Mol Med       Date:  2019-07-16       Impact factor: 12.137

7.  Multidimensional intratumour heterogeneity in neuroblastoma.

Authors:  Kristoffer von Stedingk; David Gisselsson; Daniel Bexell
Journal:  Oncotarget       Date:  2019-01-01

Review 8.  Translating insights into tumor evolution to clinical practice: promises and challenges.

Authors:  Matthew W Fittall; Peter Van Loo
Journal:  Genome Med       Date:  2019-03-29       Impact factor: 11.117

9.  Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST.

Authors:  Subhayan Chattopadhyay; Jenny Karlsson; Anders Valind; Natalie Andersson; David Gisselsson
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

10.  Anti-tumor effects of rigosertib in high-risk neuroblastoma.

Authors:  Katarzyna Radke; Karin Hansson; Jonas Sjölund; Magdalena Wolska; Jenny Karlsson; Javanshir Esfandyari; Kristian Pietras; Kristina Aaltonen; David Gisselsson; Daniel Bexell
Journal:  Transl Oncol       Date:  2021-06-09       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.